Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.883
+0.133 (2.80%)
Nov 5, 2024, 1:16 PM EST - Market open
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.
Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.
The company is headquartered in Boston, Massachusetts.
Elicio Therapeutics, Inc.
Country | United States |
Founded | 2011 |
IPO Date | Feb 5, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 32 |
CEO | Robert Connelly |
Contact Details
Address: 451 D Street, 5th Floor Boston, Massachusetts 02210 United States | |
Phone | 857-209-0050 |
Website | elicio.com |
Stock Details
Ticker Symbol | ELTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001555192 |
CUSIP Number | 28657F103 |
ISIN Number | US28657F1030 |
Employer ID | 45-2966790 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robert T. Connelly | Chief Executive Officer, President, Principal Accounting Officer, Principal Financial Officer and Director |
Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
Prof. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board |
Michael DiVecchia | Senior Vice President of Operations and Human Resources |
Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
Megan C. Filoon | General Counsel, Secretary and Compliance Officer |
Esther Welkowsky | Senior Vice President of Clinical Development |
Joy Seymour | Vice President and Head of Regulatory Affairs |
Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 2, 2022 | D/A | Filing |
Sep 13, 2022 | RW | Filing |
May 27, 2022 | D | Notice of Exempt Offering of Securities |
Nov 18, 2021 | D/A | Filing |
Nov 12, 2021 | D/A | Filing |
Oct 19, 2021 | D | Notice of Exempt Offering of Securities |
Jul 13, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 29, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 28, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 9, 2021 | DRS/A | [Amend] [Cover] Draft Registration Statement |